“This level of progression begs the question, is this a fixed-duration therapy, or is it an intermittent ... a fireside chat Monday, Pfizer CEO Albert Bourla said the company is getting ready ...

Albert Bourla, president and general manager ... with adult ADHD affecting an estimated 4% of Americans. Vertex's gene-editing therapy for sickle cell disease, Casgevy, has been given the nod ...

Executives examined some 140 medicines before zeroing in on a cancer therapy discovered by Akeso ... Kennedy Jr. and Marty Makary to lead his healthcare policy. Pfizer CEO Albert Bourla acknowledged ...

Calling it “danu” for short, CEO Albert Bourla said late-stage studies are likely ... Sarepta Therapeutics announced a large market take for its Duchenne muscular dystrophy gene therapy Elevidys, just ...

Few CEOs know the double-edged nature of dealing with US President Donald Trump as viscerally as Pfizer’s Albert Bourla. In his first term, Trump championed the $18 billion Operation Warp Speed ...

SAN FRANCISCO — At the end of a roundtable lunch with a group of reporters, Pfizer CEO Albert Bourla became impassioned. He admitted that after the company made a “big miscalculation” around ...

Chief Executive Officer Albert Bourla said at the JPMorgan Healthcare Conference on Monday. Bourla said the experts were helping Pfizer "make better and more sound decisions," and the company ...

Albert Bourla, Pfizer chairman and CEO, joins CNBC's 'Power Lunch' to discuss the company's focus for 2025, whether bird flu is the next pandemic, and more. Bollywood star Priyanka Chopra ...

Pfizer is cutting costs and refocussing its research and development (R&D) operations in a bid to maintain and grow revenues in 2025, says CEO Albert Bourla. The company achieved its 2024 goal of ...

Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and full-year 2024 and reaffirmed its 2025 financial guidance(5) provided on December 17, 2024. The ...

Need for standardized measurement methods in gene therapy Date: January 13, 2025 Source: National Institute of Standards and Technology (NIST) Summary: Scientists looked at multiple techniques ...

Shortly before the Starboard situation came to light, Pfizer in September pulled the centerpiece of the transaction—the sickle cell disease therapy ... Pfizer's CEO, Albert Bourla, Ph.D ...